Clinical trials: Influenza Viruses
Influenza
Phase 1b Influenza Vaccine Study in Healthy Subjects
The purpose of this study is to see whether a single vaccination (injection) with the investigational influenza vaccine is safe in healthy subjects.
- Trial name
- NCT01181336
- Testing
- Influenza vaccine (FLU-v), FLU-v Control
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- PepTcell Limited
Influenza
Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers
The purpose of this study is to assess the humoral immune response and safety of the parenteral formulation of the 2010/2011-season virosomal subunit influenza vaccine Inflexal V using two different HA antigen suppliers (AdImmune…
- Trial name
- NCT01229371
- Testing
- Inflexal V influenza vaccine (CSL HA Antigen) 2010, Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011
- Where
- 2 sites in Switzerland
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza
Project IMPACT Immunizations (IMProving America's Communities Together)
The primary objective of this study is to evaluate how implementing an innovative care model that provides the pharmacist access to a patient's vaccine history at the point-of-care impacts the pharmacist's ability to identify…
- Trial name
- NCT02584036
- Testing
- Vaccine administration by a pharmacist, Unmet vaccination needs identified and met, Vaccination forecast review and patient education
- Where
- 8 sites in United States
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- American Pharmacists Association Foundation
Influenza
Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations
This is a Phase II open-label study in approximately 240, and up to 400, healthy males and non-pregnant females, aged 6 months to 17 years.
- Trial name
- NCT02100436
- Testing
- Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203
- Where
- 8 sites in United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza in Humans
A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872
This open-label, four group, fixed-sequence study will evaluate the safety and pharmacokinetic interaction of AL-794 on oseltamivir, JNJ-63623872 (formerly VX-787) and probes for P-glycoprotein, CYP3A and OATP1B1 in healthy…
- Trial name
- NCT02888327
- Testing
- AL-794, Oseltamivir, Digoxin
- Where
- United Kingdom
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Influenza Virus
A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus
The purpose of this study is to determine the antiviral activity and safety of VX-787 given to healthy adult volunteers that have been inoculated with the influenza virus.
- Trial name
- NCT01561807
- Testing
- VX-787
- Where
- United Kingdom
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Acute Coronary Syndrome, Chronic Heart Failure
Influenza Vaccination During Coronavirus Disease 2019 Outbreak After Acute Coronary Syndrome and Chronic Heart Failure
Study Description: Background: Well-known fact that the number of cardiovascular diseases is on the rise during influenza epidemic.
- Trial name
- IV-ACS&CHF (NCT05232292)
- Testing
- Ultrix Quadri
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Samara Regional Cardiology Dispensary
Influenza Vaccine, Healthcare Workers
Nudge and Motivational Interviewing Interventions to Improve Influenza Vaccine Uptake Among Healthcare Workers in China
The goal of this clinical trial is to learn if nudge-based interventions and motivational interviewing work to improve influenza vaccination uptake among healthcare workers in China.
- Trial name
- NCT07157163
- Testing
- Phase 1: standardized nudge messages, Phase 1: personalized nudge messages + chatbot, Phase 2: motivational Interviewing
- Volunteers
- 4,050 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Influenza
Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04
The aim of the present study is to assess the reactogenicity and immunogenicity of a thiomersal-free influenza vaccine. For comparison, a group of subjects is administered the standard formulation of Influsplit SSW® 2003/2004.
- Trial name
- NCT00731393
- Testing
- Thiomersal free trivalent influenza split vaccine 2003/2004, GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2003/2004
- Where
- 13 sites in Germany
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immunization; Infection, Transplantation Infection
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
Influenza virus is a significant pathogen in pediatric solid organ transplant (SOT) recipients. However, these individuals respond poorly to standard-dose (SD) inactivated influenza vaccine (IIV).
- Conditions
- Immunization; Infection, Transplantation Infection, Influenza
- Trial name
- PSOT (NCT05947071)
- Testing
- Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine
- Where
- 10 sites in United States
- Volunteers
- 312 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
A Prospective Epidemiological Cohort Study Evaluating Occurrences of Influenza-like Illness.
This Prospective epidemiological cohort study is being conducted in order to generate epidemiological data in support of Osivax's clinical development of a broad spectrum influenza vaccine based upon the internal influenza…
- Trial name
- NCT05184387
- Testing
- Blood samples
- Where
- Belgium
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Osivax
Influenza, Streptococcus Pneumoniae
Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years
Recent reviews have highlighted the unpredictability and complexity of immune interference when multivalent conjugate vaccines are co-administered with other pediatric vaccines.
- Trial name
- NCT02215863
- Testing
- Fluad and Prevenar13, Fluad, Prevenar13
- Where
- 3 sites in South Korea
- Volunteers
- 1,195 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
Influenza
Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children
This study is a randomized controlled trial (RCT) comparing adjuvanted influenza vaccine (AV) to unadjuvanted inactivated influenza vaccine (IIV). Children in Hutterite colonies in Alberta and Saskatchewan will receive AV or IIV.
- Trial name
- NCT02871206
- Testing
- Fluad, Fluzone
- Where
- Canada
- Volunteers
- 3,425 people, healthy volunteers welcome
- Sponsor
- McMaster University
Influenza, Gammopathy
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients
A Pilot Study utilizing high dose trivalent influenza vaccine dose in a booster dosing schedule for patients with monoclonal gammopathies stratified by disease status
- Trial name
- SHIVERING (NCT02267733)
- Testing
- Fluzone
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Yale University
Influenza Disease
Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases
This phase III is designed to confirm the previous trial results evaluating the safety, clinical tolerability and immunogenicity of the 2006-2007 formulation of Novartis Vaccines' adjuvanted influenza vaccine and subunit…
- Trial name
- NCT00519064
- Testing
- Adjuvanted influenza vaccine
- Where
- Italy
- Volunteers
- 361 people
- Sponsor
- Novartis Vaccines
SARS-CoV-2, Influenza
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
The primary goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines and to the individual vaccines alone in healthy participants.
- Trial name
- NCT05375838
- Testing
- mRNA-1073, mRNA-1010, mRNA-1273
- Where
- 14 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza, Human, Pneumonia
Rapid Assessment of and Prophylaxis for Influenza in Dwellers of Long-term Care Facilities
RAPID-LTCF is a stratified, block-randomized controlled trial to assess the effectiveness of a simple ARI case definition, rapid influenza diagnostic test (RIDT) with wireless transmission of results, and provision of infection…
- Trial name
- Rapid-LTCF (NCT02964871)
- Testing
- Sofia Fluorescent Immunoassay Analyzer Influenza A+B, Usual care
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
FLU
Wastewater Epidemiology to Document the Circulation of Influenza Viruses
Primary objective: To evaluate the wastewater surveillance strategy for anticipating the circulation of influenza virus strains in the general population and among hospitalized patients.
- Trial name
- EPI-FLU-EAU (NCT07880834)
- Volunteers
- 300 people
- Sponsor
- Central Hospital, Nancy, France
Influenza
Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children
A total of 88 children between 2 and 9 years of age will be randomized to receive a two dose schedule of either licensed live attenuated trivalent seasonal influenza vaccine (LAIV) or licensed inactivated seasonal influenza…
- Trial name
- NCT01246999
- Testing
- Live attenuated Influenza vaccine, Trivalent Influenza Vaccine, TIV followed by LAIV
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Flu, Human
Study of the Safety, Tolerability and Immunogenicity of an Intranasal Influenza Vaccine Administered to Healthy Adults
The objectives of this study were to assess the safety and tolerability of DCB07010 when given intranasally at escalating dose levels of 7.5μg, 15μg, 30μg and 45μg, in combination with 22.5μg of influenza HA antigen (7.5μg HA of…
- Trial name
- NCT03293732
- Testing
- DCB07010, HA antigens
- Where
- Taiwan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Advagene Biopharma Co. Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.